EWTX · Edgewise Therapeutics Inc
United States · RS rating 55 · As of 2026-11-03
| Price | 37.68 USD |
|---|---|
| 1-day change | -1.1% |
| RS rating (overall / 1M / 3M / 12M) | 55 / 42 / 36 / 94 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 31 / 35 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -20.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +22.1% |
| Market cap (USD) | $3.4B |